|
Parameters
|
cisplatin (N = 137)
|
carboplatin (N = 76)
|
P-value
|
|---|
|
Age (years)
|
51.6 (21–67)
|
53.8 (35–70)
|
0.051
|
|
Maximal diameter of primary tumor(cm)
|
4.5 (2–8)
|
4.3(2–9)
|
0.4
|
|
Stage
| | |
0.09
|
|
IIB
|
91(66.4 %)
|
43(56.6 %)
|
|
IIIA
|
0
|
2(2.6 %)
|
|
IIIB
|
44(32.1 %)
|
31(40.8 %)
|
|
IVA
|
2(1.5 %)
|
0
|
|
Pelvic Lymph nodes
| | |
0.63
|
|
No
|
72(52.6 %)
|
45(59.2 %)
|
|
Yes
|
14(10.2 %)
|
6(7.9 %)
|
|
Unknown
|
51(37.2 %)
|
25(32.9 %)
|
|
Histology
| | |
0.4
|
|
SCCA
|
114(83.2 %)
|
66(86.8 %)
|
|
ACA
|
21(15.3 %)
|
9(11.8 %)
|
|
Others
|
2(1.5 %)
|
1(1.3 %)
|
|
Histologic grade
| | |
0.66
|
|
1
|
18(14.8 %)
|
9(13.4 %)
|
|
2
|
78(63.9 %)
|
47(70.1 %)
|
|
3
|
26(21.3 %)
|
11(16.4 %)
|
|
Cycles
| | |
0.02
|
|
Up to 4 cycles
|
38 (27.7 %)
|
10(13.2 %)
|
|
5 to 6 cycles
|
99(72.3 %)
|
66(86.8 %)
|
|
Total treatment time (days)
|
56.8 (34–114)
|
56(43–173)
|
0.39
|
|
Median follow-up time (months)
|
39.8(6–69)
|
40.6(6–69)
|
0.76
|
-
Note: SCCA squamous cell carcinoma, ACA adenocarcinoma
